Ascendiant Capital Maintains Buy on IGC Pharma, Raises Price Target to $3.75
Portfolio Pulse from Benzinga Newsdesk
Ascendiant Capital has maintained a Buy rating on IGC Pharma and raised its price target from $3.5 to $3.75, indicating a positive outlook for the company's stock.
September 03, 2024 | 9:49 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Ascendiant Capital has maintained a Buy rating on IGC Pharma and increased the price target from $3.5 to $3.75, suggesting a positive short-term outlook for the stock.
The increase in the price target from $3.5 to $3.75 by Ascendiant Capital indicates a positive sentiment towards IGC Pharma's future performance. This is likely to boost investor confidence and could lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100